Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine
Abstract
The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N‐methyl‐D‐aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine increases the decarboxylation rate of 6‐[ 18F]fluoro‐L‐DOPA (FDOPA), an exogenous substrate for DDC, in healthy human brain. Radioactivity concentrations in brain tissue of neurologically normal volunteers (n = 5) injected intravenously with FDOPA (∼4.5 mCi) were recorded by positron emission tomography (PET) for 120 min, first in a baseline condition, and again following three consecutive days of treatment with amantadine (100 mg/day, p.o.). Data from four telencephalic regions of interest containing appreciable DDC activity were analyzed with the tissue slope‐intercept plot, using cerebellar cortex as the reference tissue, to estimate a coefficient of in situ FDOPA decarboxylation (k3r, min−1). Mean estimates of k3r were increased following amantadine treatment in caudate nucleus (+12%), putamen (+28%), ventral striatum (+27%), and frontal cortex (+9%). For an initial confidence level of 95%, paired one‐sided Student's t‐tests with Bonferroni correction for multiple comparisons revealed a statistically significant drug effect in ventral striatum. Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti‐parkinsonian properties of amantadine. Nonetheless, PET studies in parkinsonian patients using higher, clinically effective doses of amantadine may reveal more pronounced enhancements of cerebral DDC activity. Synapse 34:313–318, 1999.Keywords
This publication has 49 references indexed in Scilit:
- Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic l-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the ratBrain Research, 1998
- [3H]DOPA Formed from [3H]Tyrosine in Living Rat Brain Is Not Committed to Dopamine SynthesisJournal of Cerebral Blood Flow & Metabolism, 1998
- On the accuracy of an [18F]FDOPA compartmental model: evidence for vesicular storage of [18F]fluorodopamine in vivoJournal of Neuroscience Methods, 1997
- Regulation of DOPA Decarboxylase Activity in Brain of Living RatJournal of Neurochemistry, 1995
- The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementiasBrain Research Reviews, 1995
- MRI-PET Correlation in Three Dimensions Using a Volume-of-Interest (VOI) AtlasJournal of Cerebral Blood Flow & Metabolism, 1991
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989
- Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521Biochemical Pharmacology, 1987
- The Metabolism of [18F]6‐Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Hooded RatJournal of Neurochemistry, 1987
- Use of Amantadine in Parkinson's Disease. Results of a Double-blind TrialBMJ, 1970